Qiagen NV at Barclays Global Healthcare Conference Transcript
Good morning, everybody. I'm Luke Sergott from Life Science Tools Diagnostics here at Barclays. With me, it's a pleasure to have Roland Sackers and John Gilardi of QIAGEN. It's been a long time, good to see you in person. So with that, if you guys want to open with a little comments, then we can dig in.
Yes, why not. And again, thanks for having us and also for us, I think the first physical conference, at least in the U.S. for quite some while. It's good to be back. I thought (inaudible) but again. Yes, I think it's good to be -- and also good to report out on some of the developments we see. And as you know, we put out a very good fiscal year '21, clearly had a strong performance, actually both overall, what we call COVID-related business, which I think is probably more important for us also very strong performance of the non-COVID side, we have seen now, I think, consecutive quarters where we were able not only
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
